#$%^&*AU2012201853B220130627.pdf#####ABSTRACT The use of dimiracetam in the treatment of chronic pain is disclosed. At doses higher than those previously disclosed in relation with its cognition enhancing 5 activity (i.e. amelioration of learning and memory), dimiracetam was able to completely revert hyperagesia or allodynia associated with several animal models of chronic pain. Dimiracetam showed high activity in iatro-genic neuropathies associated with antiviral and chemotherapeutic drug treatments and in painful conditions caused by osteoarthritis. In addition, dimiracetam was 10 devoid of toxicity even at a dose 10-fold higher than the highest therapeutic dose. The possibility of treating such debilitating pathologies with a highly effective and essentially non-toxic compound is therefore disclosed.
